Company: SXTPW
Filing Date: 2025-01-30
Form Type: 424B5
Source: 0001213900-25-008098
Chunk: 51

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-01-30
Form: 424B5
Chunk 51
---
 atovaquone and azithromycin which is extended to six weeks in the immunosuppressed, who may also experience  
 relapses requiring multiple hospitalizations.12 This is much longer than equivalent serious parasitic diseases such as                 
 malaria where the goal is a three-day regimen. In a recently published case series Tafenoquine in combination with standard of care    
 cured 80% of immunosuppressed patients with relapsing babesiosis and the investigators stated in a press release that “Tafenoquine     
 is going to make a huge difference, I think, in people who are severely immunocompromised.”                                            
 13                                                                                                                                     |

| ● | Prevention                                                                                                                                 
 of Tick-Borne Diseases. Post-exposure prophylaxis or early treatment with, respectively, a single dose or several week regimen             
 of doxycycline following a tick-bite is a recognized indication to prevent the complications of Lyme disease. There may be more than       
 400,000 such tick bites in the United States requiring medical treatment each year. This estimate is based on the observation that         
 approximately 50,000 tick bites are treated in U.S. hospital emergency rooms each year; however, this calculation represents only          
 about 12% of actual treated tick bites based on observations from comparable ex-U.S health systems.14 Unlike Lyme disease,                 
 there is no characteristic rash associated with early infection and no reliable diagnostic tests. Thus, an individual bitten by a          
 tick cannot know whether they have also been infected with babesiosis. It is likely that a drug proven to be effective for this indication 
 for babesiosis would also be used in conjunction with Lyme prophylaxis.                                                                    |

Treatment and Prevention of Fungal Infections We are evaluating Tafenoquine for potential utility in the following fungal diseases:

| ● | Treatment                                                                                  
 of Candida infections. According to the CDC, there are 50,000 reported                     
 cases of candidiasis (a type of fungal infection) each year in the United States and up to 
 1,900 clinical cases of C. auris, for which there are few available treatments.15          
 Since it has broad-spectrum activity against drug-resistant Candida spp in culture,        
 Tafenoquine, has the potential to be a market leading therapy for treatment/prevention of  
 C. auris, and to be added to the standard of care regimens for other Candida infections.16 |

| 10 | This                                                                                               
 estimate is based on the observations of Krugeler et al